254 related articles for article (PubMed ID: 34130525)
1. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
Frank F; Ulmer H; Sidoroff V; Broessner G
Cephalalgia; 2021 Oct; 41(11-12):1222-1239. PubMed ID: 34130525
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
3. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
4. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
[TBL] [Abstract][Full Text] [Related]
5. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
[TBL] [Abstract][Full Text] [Related]
6. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
[TBL] [Abstract][Full Text] [Related]
7. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
Pellesi L; Do TP; Ashina H; Ashina M; Burstein R
Headache; 2020 Jun; 60(6):1056-1065. PubMed ID: 32437038
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
9. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives NJ; Clarke CE; Sinclair AJ
BMJ Open; 2019 Jul; 9(7):e027953. PubMed ID: 31315864
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
Jackson JL; Kuriyama A; Hayashino Y
JAMA; 2012 Apr; 307(16):1736-45. PubMed ID: 22535858
[TBL] [Abstract][Full Text] [Related]
11. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
Lampl C; MaassenVanDenBrink A; Deligianni CI; Gil-Gouveia R; Jassal T; Sanchez-Del-Rio M; Reuter U; Uluduz D; Versijpt J; Zeraatkar D; Sacco S
J Headache Pain; 2023 May; 24(1):56. PubMed ID: 37208596
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review.
She T; Chen Y; Tang T; Chen M; Zheng H
Medicine (Baltimore); 2020 Jan; 99(5):e18929. PubMed ID: 32000407
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison.
Lu J; Zhang Q; Guo X; Liu W; Xu C; Hu X; Ni J; Lu H; Zhao H
Front Pharmacol; 2021; 12():631204. PubMed ID: 34012392
[No Abstract] [Full Text] [Related]
14. Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis.
Zheng H; Huang SL; Chen YY; Tang TC; Qin D; Chen M
Acta Neurol Scand; 2021 May; 143(5):558-568. PubMed ID: 33393102
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
16. 2022 Taiwan Guidelines for Preventive Treatment of Migraine.
Wu JW; Yang CP;
Acta Neurol Taiwan; 2022 Sep; 31(3)():164-202. PubMed ID: 36089629
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging evidence-based treatment options in chronic migraine: a narrative review.
Agostoni EC; Barbanti P; Calabresi P; Colombo B; Cortelli P; Frediani F; Geppetti P; Grazzi L; Leone M; Martelletti P; Pini LA; Prudenzano MP; Sarchielli P; Tedeschi G; Russo A;
J Headache Pain; 2019 Aug; 20(1):92. PubMed ID: 31470791
[TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin in the Treatment of Headache.
Becker WJ
Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33348571
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
